AMOYTOP(SH:688278) Donghai Securities·2024-10-15 12:40Investment Rating - The report maintains a "Buy" rating for the company [9]. Core Views - The company shows strong revenue growth and high confidence in its development, highlighted by an ambitious equity incentive plan [9]. - The antiviral treatment population is expanding, and the core product, Pegbivac, is expected to continue its sales growth [9]. - The innovative pipeline is gradually entering a harvest period, with several products expected to launch soon [10]. Summary by Sections Company Overview - The company, established in 1996, is a leader in the development of long-acting recombinant protein drugs, focusing on viral hepatitis, malignant tumors, and immunotherapy [16]. - It has launched five products, all included in the national medical insurance, with Pegbivac showing exceptional performance in the clinical cure of hepatitis B [17]. Financial Performance - From 2018 to 2023, the company's revenue grew from 448 million to 2.1 billion yuan, with a compound annual growth rate (CAGR) of 36.19%, and net profit increased from 16 million to 555 million yuan, with a CAGR of 103.28% [23]. - In the first half of 2024, the company achieved a revenue of 1.19 billion yuan, a year-on-year increase of 31.68%, and a net profit of 304 million yuan, up 50.53% year-on-year [23]. Market Potential - The chronic hepatitis B patient population in China is substantial, with 79.74 million HBV infected individuals, including 20 to 30 million chronic hepatitis B patients [9][39]. - Pegbivac is the only long-acting interferon product on the market in China, with significant potential for sales growth as the treatment population expands [12]. Product Pipeline - The company has a robust pipeline with several products expected to launch soon, including long-acting G-CSF and long-acting growth hormone, which are anticipated to capture significant market share [10][30]. - The company is actively exploring new treatment options for hepatitis B, including collaborations for new drug development [27]. Equity Incentive Plan - In August 2024, the company announced an equity incentive plan with ambitious performance targets for net profit growth over the next three years, reflecting strong confidence in its long-term development [31].